A crossover investor in the life sciences

Merlin Nexus has been investing in private and public life sciences companies since 2001, with a proven track record of performance.

Merlin Nexus is an investment management company focused on crossover private equity investing in the life sciences industry.

Merlin Nexus invests globally in private and public healthcare companies and manages several crossover private equity funds with capital commitments totaling $200 million. Our investor base consists of financial institutions, funds of funds, family offices and high net worth individuals.

DOMINIQUE SÉMON, CFA

Robertson Stephens - Head, Healthcare Private Capital Markets (1998-2001)
New York Life - Portfolio Manager, Healthcare Private Equity (1993-1998)
Citibank - Biotechnology Research Analyst, Asset Management (1989-1992)
Biogen - Head, Sequencing Lab (1983-1987)

New York University, MS, Economics (1995)
University of Neuchâtel (Switzerland), Licence ès Science, Molecular Biology (1982)


CHRISTIAN RICHARD

Schering-Plough Research Institute - Research Scientist (1997-2001)
New York University School of Medicine - Research Scientist (1993-1997)

Stern School of Business, New York University, MBA, Finance (2002)
New York University, MS, Cellular Biochemistry (1997)
Purchase College, BS, Cellular/Molecular Biology (1993)


ALBERTO BIANCHINOTTI, CPA

Merlin BioMed Group - Healthcare Analyst (2004-2006)
Anchin, Block & Anchin , LLP - Audit & Tax Supervisor, Financial Services (1999-2004)

Binghamton University, BS, Accounting (1999)

Performance Redefined

Merlin Nexus believes the pre- and post-IPO segment is a source of superior life sciences investment opportunities. This investment "space" generates two distinct sets of opportunities: private investments in late-stage private companies and private investments in public companies (PIPES).

Our crossover strategy enables us to take advantage of valuation disparities between the private and public markets. Unlike venture capital funds, Merlin Nexus funds are characterized by relatively high liquidity and short fund term. Our strategy minimizes binary risk and results in balanced returns.